Recent

% | $
Quotes you view appear here for quick access.

Skullcandy, Inc. Message Board

cash2go 142 posts  |  Last Activity: Aug 25, 2015 4:45 PM Member since: Feb 8, 2006
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • RX is not the same as free markets. Good luck to ManKind all the patients are rooting for them

  • Reply to

    Briefs vs. Oral A.

    by polgringo Jul 17, 2015 10:23 AM
    cash2go cash2go Jul 17, 2015 7:38 PM Flag

    $30,000/day still going to Pharmathene. Siga management and it's cohorts are pocketing how much a day while this continues? Siga shareholders looking at their ROI flying out the window. Siga management doesn't seem to have any concern of ever actually returning anything to shareholders.

  • Millions in Siga bonus money being paid out in stock grants?

  • cash2go cash2go Jun 16, 2015 2:52 AM Flag

    Sept 2006
    Results announced that primates injected with lethal dose of smallpox treated with -246 all lived and had no or lower lesion burden. Primates not given 246 died.
    Study impressed NIH and awarded tens of millions to complete study to gain approval to stockpile -246
    Congress had special funding approved and set aside $5B to acquire bioterror solutions from biotech. Smallpox & Anthrax were considered the top two concerns to focus on when using the $5 billion.

    CBLI - if they had a drug 100% effective in primate trials and showed no serious side effects in radiation exposure levels proven 100% fatal. With NIH funding in tens of millions granted to get their product to the finish line. Also, have billions approved by Congress set aside for stocking of the medication. With all those factors your speculation of value for CBLI would be interesting. Have you done any calculations and do you have the degree of certainty on a coming BARDA purchase?

    Siga & Barda were talking in excess of $2 billion contract within a couple of years from Sept '06.

    What are you speculating on with CBLI. And the only thing not speculative is death, so everything listed in DOW or NASDAQ is based on speculation.

    Please update us on you CBLI speculation and any data you have. I may join you in the investment.

  • Reply to

    8 Billion dollars of debt...

    by kored35 Jul 8, 2015 4:49 PM
    cash2go cash2go Jul 8, 2015 5:18 PM Flag

    9th consecutive quarter in which it has booked more than $100 million per quarter in restructuring charges? At beginning of quarter AA estimates were +0.30. Wall Street painting another balloon green before it bursts. Read the 8K folks.

  • cash2go cash2go Jul 30, 2015 3:08 PM Flag

    One in a million. A post on long term implications. Wish there were boards for traders and one for investing

    GLTA

  • cash2go by cash2go Jun 9, 2015 2:01 AM Flag

    Ask any diabetic using 4 shots a day if he likes taking shots. The answer will be NO. If you have a better mousetrap it will be the one the consumers eventually go to.

    Give yourself 4 shots or more a day and see if you ever begin to like doing it. 95 to 100 percent will understand what I am saying. In 2 or 3 years this will be huge. If you day traded the first few months I hope you made money. Big money in the buy and hold. We have found a better mouse trap so buy into it sit on it and wait for it's adoption rate reach parabolic stage. Investors only who can wait.

  • Building cash reserves in about the most favorable way possible, Oculus Innovative Sciences (NASDAQ: OCLS) announced on March 16 that it is padding its bank account without any dilution by selling part, and eventually all, of its stake in Ruthigen (NASDAQ: RTGN), a company it spun out into a separate public entity last year. Some may have seen this coming as Oculus said in January that it penned an agreement to sell two million shares of RTGN for $5.5 million to existing Ruthigen shareholders “if” a merger happens for Ruthigen.

    RTGN divesture added to the $5.3 million raised in January plus the $2.2 million on hand at the end of 2014 (plus revenue in 2015, less expenses) has Oculus’ cash on hand nearing its $11.8 million market capitalization. O

  • Reply to

    Non dilutive financing

    by cash2go Jun 11, 2015 2:51 PM
    cash2go cash2go Jun 11, 2015 3:31 PM Flag

    Looks like a good buyout for a small or medium size company that has an effective sales staff in place.

    Plenty of interest in the cash position when it comes to a buyout.

  • Reply to

    Oral Arguments Coming

    by jomamaduntoldme Jun 14, 2015 7:14 AM
    cash2go cash2go Jun 24, 2015 12:59 PM Flag

    I'm thinking they will do all possible to wrap this up while Parsons is on board. Parsons background and the many hours put in the case are too valuable.

    Of course Siga may not see it that way. Delay, delay, delay...while the contract money comes in and is cost expensed while salaries are paid expense accounts paid....Siga says eight years of delay has been very good for management pockets. More will be good.

  • Reply to

    News release

    by ardmiami Jul 8, 2015 11:44 AM
    cash2go cash2go Jul 8, 2015 11:53 AM Flag

    Anthrax back on the table? Immunovaccine announced they had tried their vaccine technology with multiple Anthrax vaccines a couple of months ago and had seen protection in animal models after a single dose. If NIH funding is announced I would guess Pharmathene's anthrax vaccine stood out in the trial. That would be a big boost to future valuation of this one. Things could get interesting over the next year.

  • Not according to NASADAQ site which list each trade made over last few minutes.

  • Reply to

    News release

    by ardmiami Jul 8, 2015 11:44 AM
    cash2go cash2go Jul 8, 2015 12:18 PM Flag

    "Immunovaccine has granted PharmAthene exclusive worldwide rights to use DepoVax for the development and commercialization of the novel single dose anthrax vaccine."

    NIH funding? Boom.

    GLTA

  • Dec 20, 2006

    VaxGen Inc. said late Tuesday that the Department of Health and Human Services (HHS) has terminated the company's $877.5 million contract to provide 75 million doses of a modern anthrax vaccine for civilian biodefense.

    Brisbane-based VaxGen (Pink Sheets:VXGN) said HHS based the decision on its determination that VaxGen "failed to successfully cure the condition endangering performance" and failed to meet a milestone imposed by HHS that required VaxGen to initiate a clinical trial of the vaccine candidate by Dec. 18.

    ($877.5 million) - looking forward to the next quarterly conference call.

  • cash2go cash2go Jul 13, 2015 7:36 PM Flag

    then the trial with Sparvax added to Depovax and the survival results:

    Rabbits were exposed to a lethal dose of the anthrax causing bacterial spores (B. anthracis) 28 days following a single vaccination. The DepoVax/rPA vaccines provided good protection to animals against anthrax with a single dose, protecting a total of 15 of 24 animals across the three different rPA sources. As expected, control animals injected with a saline solution all succumbed to the anthrax challenge. Animals given a placebo DepoVax vaccine with no antigen also succumbed to anthrax, demonstrating that protection is mediated by the combination of DepoVax and rPA

  • Preliminary findings from the immunogenicity studies include:
    • A single dose of DepoVaxTM-formulated anthrax vaccine produced sustained toxin-neutralizing antibody (“TNA”) titers detected in six of ten animals, starting between day 21 and 49. Animals receiving one dose of Biothrax had no detectable TNA titers.
    • When a second dose of the DepoVaxTM-formulated vaccine was delivered, there was a significant increase in anthrax TNAs in all immunized animals within one week of the booster administration

  • cash2go cash2go Jul 23, 2015 2:24 PM Flag

    Furthermore, this Court enjoys remedial flexibility to depart from strict application of the ordinary forms of relief where circumstances require.30 Nevertheless, courts of equity should attempt to balance that flexibility by a measure of concomitant restraint to
    minimize uncertainty.

  • Reply to

    Now moving into emotional trading

    by cash2go Jul 24, 2015 11:56 AM
    cash2go cash2go Jul 24, 2015 1:37 PM Flag

    Forced selling and lack of buyers is what crashed the entire market into the entry of a lifetime. Looks like AUY is heading there. A few months of below $900 gold will BK a lot of marginal players unable to handle debt loads.
    How long will it take for buyers to creep back into oil? First "real" sign of inflation which may be a couple years off.

  • cash2go cash2go Jul 23, 2015 2:33 PM Flag

    The Supremes advised Parson's to use best expert opinion on this type of dispute to determine the award. That is where Parsons went way conservative and ended up with $130M that has nothing near the billions both parties thought -246 was worth in Sept '06. With interest adding $30,000 daily to the ill intent boyz liability we can all hope this comes to an end soon.

    GLTA, but the boyz (they have already pocketed tens of millions in the money flow and cost of goods, more than they deserve)

  • cash2go cash2go Jul 23, 2015 2:18 PM Flag

    the Supreme Court held that “where the parties have a Type II preliminary agreement to negotiate in good faith, and the trial judge makes a factual finding, supported by the record, that the parties would have reached an agreement but for the defendant’s bad faith negotiations, the plaintiff is entitled to recover contract expectation damages.” Further, the court found that the factual conclusions made by the Court of Chancery support a finding that the LATS was a Type II preliminary agreement and that SIGA and Pharmathene could not, in good faith, propose terms of the definitive licensing agreement that were inconsistent with the LATS. Because this was the first time the Delaware Supreme Court addressed whether Delaware law recognizes Type II preliminary agreements or whether a plaintiff is entitled to recover expectation damages in connection with a breach of an obligation to negotiate a definitive agreement in good faith, the Supreme Court reversed the Court of Chancery’s damages award for reconsideration consistent with its ruling.

SKUL
7.08+0.18(+2.61%)Aug 28 4:00 PMEDT